Infrequent epigenetic dysregulation of CIP/KIP family of cyclin-dependent kinase inhibitors in multiple myeloma [12]

Leukemia

Volumn 19, Issue 12, 2005, Pages 2352-2355

  Chim, C S ^a   Liang, R ^a   Fung, T K ^a   Kwong, Y L ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DNA METHYLTRANSFERASE; PROTEIN P16INK4A; PROTEIN P18; PROTEIN P19; PROTEIN P57;

BONE MARROW BIOPSY; CANCER SUSCEPTIBILITY; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL LINE; CELL PROLIFERATION; DNA DAMAGE; DNA METHYLATION; GENETIC EPIGENESIS; GENETIC SUSCEPTIBILITY; HAPLOIDY; HUMAN; LETTER; MULTIPLE MYELOMA; MYELOMA CELL; NUCLEIC ACID BASE SUBSTITUTION; OSTEOLYSIS; PLASMACYTOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE;

EID: 28544442914     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403904     Document Type: Letter

References (11)

1. Malumbres M, Barbacid M. To cycle or not to cycle: A critical decision in cancer. Nat Cancer Rev 2001; 1: 222-231.
2. Lee MH, Yang HY. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 2001; 58: 1907-1922.
3. Chim CS, Liang R, Kwong YL. Gene promoter hypermethylation in hematologic malignancies. Hematol Oncol 2002; 20: 167-176.
4. Chim CS, Fung TK, Cheung J, Liang R, Kwong YL. SOCS1 and SHP1 hypermethylation in multiple myeloma: Implications for epigenetic activation of the Jak/STAT pathway. Blood 2004; 103: 4630-4635.
5. Chim CS, Fung TK, Liang R. Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS. Leukemia 2003; 17: 2533-2535.
6. Ying J, Srivastava G, Gao Z, Zhang X, Murray P, Ambinder R et al. Promoter hypermethylation of the cyclin-dependent kinase inhibitor (CDKI) gene p21WAF1/CIP1/SDI1 is rare in various lymphomas and carcinomas. Blood 2004; 103: 743-746.
7. Shiohara M, el-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84: 3781-3784.
8. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/ Kip1 in human malignancies. Cancer Res 1995; 55: 2266-2269.
9. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002; 8: 1153-1160.
10. Li Y, Nagai H, Ohno T, Yuge M, Hatano S, Ito E et al. Aberrant DNA methylation of p57 (KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood 2002; 100: 2572-2577.
11. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003; 3: 233-245.